BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37973486)

  • 1. Cerebral Metabolic Signature of Chronic Benzodiazepine Use in Nondemented Older Adults: An FDG-PET Study in the MEMENTO Cohort.
    Gallet Q; Bouteloup V; Locatelli M; Habert MO; Chupin M; Campion JY; Michels PE; Delrieu J; Lebouvier T; Balageas AC; Surget A; Belzung C; Arlicot N; Ribeiro MS; Gissot V; El-Hage W; Camus V; Gohier B; Desmidt T;
    Am J Geriatr Psychiatry; 2024 Jun; 32(6):665-677. PubMed ID: 37973486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzodiazepine use and neuroimaging markers of Alzheimer's disease in nondemented older individuals: an MRI and 18F Florbetapir PET study in the MEMENTO cohort.
    Gallet Q; Bouteloup V; Locatelli M; Habert MO; Chupin M; Delrieu J; Lebouvier T; Robert G; David R; Bulteau S; Balageas AC; Surget A; Belzung C; Arlicot N; Ribeiro MJ; Barantin L; Andersson F; Cottier JP; Gissot V; El-Hage W; Camus V; Gohier B; Desmidt T;
    Neuropsychopharmacology; 2022 Apr; 47(5):1114-1120. PubMed ID: 34893757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benzodiazepine use and brain amyloid load in nondemented older individuals: a florbetapir PET study in the Multidomain Alzheimer Preventive Trial cohort.
    Desmidt T; Delrieu J; Lebouvier T; Robert G; David R; Balageas AC; Surget A; Belzung C; Arlicot N; Ribeiro MJ; Payoux P; Vellas B; El-Hage W; Tavernier E; Camus V;
    Neurobiol Aging; 2019 Dec; 84():61-69. PubMed ID: 31514054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebral Glucose Metabolism is Associated with Verbal but not Visual Memory Performance in Community-Dwelling Older Adults.
    Gardener SL; Sohrabi HR; Shen KK; Rainey-Smith SR; Weinborn M; Bates KA; Shah T; Foster JK; Lenzo N; Salvado O; Laske C; Laws SM; Taddei K; Verdile G; Martins RN
    J Alzheimers Dis; 2016 Mar; 52(2):661-72. PubMed ID: 27031482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons.
    Knopman DS; Jack CR; Wiste HJ; Lundt ES; Weigand SD; Vemuri P; Lowe VJ; Kantarci K; Gunter JL; Senjem ML; Mielke MM; Roberts RO; Boeve BF; Petersen RC
    Neurobiol Aging; 2014 Sep; 35(9):2096-106. PubMed ID: 24702820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of ApoE ε4 on longitudinal brain region-specific glucose metabolism in patients with mild cognitive impairment: a FDG-PET study.
    Paranjpe MD; Chen X; Liu M; Paranjpe I; Leal JP; Wang R; Pomper MG; Wong DF; Benzinger TLS; Zhou Y;
    Neuroimage Clin; 2019; 22():101795. PubMed ID: 30991617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arterial spin labeling versus
    Dolui S; Li Z; Nasrallah IM; Detre JA; Wolk DA
    Neuroimage Clin; 2020; 25():102146. PubMed ID: 31931403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S; Yamasaki H
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis of conversion of mild cognitive impairment to Alzheimer's dementia by voxel-wise Cox regression based on FDG PET data.
    Sörensen A; Blazhenets G; Rücker G; Schiller F; Meyer PT; Frings L;
    Neuroimage Clin; 2019; 21():101637. PubMed ID: 30553760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tracer-specific reference tissues selection improves detection of
    Li Y; Ng YL; Paranjpe MD; Ge Q; Gu F; Li P; Yan S; Lu J; Wang X; Zhou Y;
    Hum Brain Mapp; 2022 May; 43(7):2121-2133. PubMed ID: 35165964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
    Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
    J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer's disease.
    Croteau E; Castellano CA; Fortier M; Bocti C; Fulop T; Paquet N; Cunnane SC
    Exp Gerontol; 2018 Jul; 107():18-26. PubMed ID: 28709938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparability of [
    Rodriguez-Vieitez E; Leuzy A; Chiotis K; Saint-Aubert L; Wall A; Nordberg A
    J Cereb Blood Flow Metab; 2017 Feb; 37(2):740-749. PubMed ID: 27107028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting Imminent Progression to Clinically Significant Memory Decline Using Volumetric MRI and FDG PET.
    Stonnington CM; Chen Y; Savage CR; Lee W; Bauer RJ; Sharieff S; Thiyyagura P; Alexander GE; Caselli RJ; Locke DEC; Reiman EM; Chen K
    J Alzheimers Dis; 2018; 63(2):603-615. PubMed ID: 29630550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
    J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.
    Förster S; Yousefi BH; Wester HJ; Klupp E; Rominger A; Förstl H; Kurz A; Grimmer T; Drzezga A
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1927-36. PubMed ID: 22926714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex modulates the ApoE ε4 effect on brain tau deposition measured by
    Liu M; Paranjpe MD; Zhou X; Duy PQ; Goyal MS; Benzinger TLS; Lu J; Wang R; Zhou Y
    Theranostics; 2019; 9(17):4959-4970. PubMed ID: 31410194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What are the Most Frequently Impaired Markers of Neurodegeneration in ADNI Subjects?
    Andriuta D; Moullart V; Schraen S; Devendeville A; Meyer ME; Godefroy O;
    J Alzheimers Dis; 2016; 51(3):793-800. PubMed ID: 26923012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.